Health-Related Quality of Life and Utility Scores of Lung Cancer Patients Treated with Traditional Chinese Medicine in China

Liu, Lei; Wei, Yi‐Ming; Teng, Yue; J, Yan; F, Li; Chen, Y

doi:10.2147/ppa.s344622

Cited by 3 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies reported that Chinese medicine played a unique role in improving symptoms and quality of life (23)(24)(25). Significantly as the process of tumor development, when the tumor load gradually increases, the consumption of the host also gradually increases, and the quality of life in all aspects, such as emaciation, loss of appetite, fatigue, poor nutritional status, poor spirit, physical strength, and decreased activity tolerance 6…”

Section: Discussionmentioning

confidence: 99%

Chinese Medicine Enhancing Response Rates to Immunosuppressant PD-L1 Inhibitor and Improving the Quality of Life of Hepatocellular Carcinoma-Bearing Mice

Liu

et al. 2023

Iran J Pharm Res

View full text Add to dashboard Cite

Background: Malignant tumors are a significant disease endangering human health. Chinese Medicine (CM) plays an important role in comprehensive and holistic tumor treatment. Objectives: We aimed to investigate whether CM combined with the immunosuppressant PD-1/PD-L1 inhibitor has a good synergistic effect and can significantly improve response rates for the immunosuppressant. Methods: We combined CM with immunosuppressant in treating six-week-old hepatocellular carcinoma-bearing mice and compared the outcomes of groups undergoing different interventions: blank group, control group, CM group, PD-L1 inhibitor group, and CM + PD-L1 inhibitor group, with ten mice in each group. The quality of life was evaluated along with the tumor inhibition effects and growth rates. Results: CM significantly reduced tumor load and improved the quality of life of cancer-bearing mice. The survival rate was 81.8% in the control group, 100% in the CM group, 90.9% in the PD-L1 inhibitor group, and 100% in the combined group in the first week. The survival rate was 45.5% in the control group, 54.5% in the CM group, 81.8% in the PD-L1 inhibitor group, and 81.8% in the combined group in the second week. 38% mice in the CM+PD-L1 inhibitor group with smaller tumor size than the average of the control group, which was much higher than other treatment groups. CM also reduced the expression of JAK2 mRNA and STAT3 mRNA, although not significantly (P > 0.05), and reduced PD-L1 mRNA in tumor tissue compared to the control group (P < 0.05). Conclusions: CM had a synergistic effect on PD-L1 inhibitors and increased response rates to PD-L1 inhibitor treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Chinese Medicine Enhancing Response Rates to Immunosuppressant PD-L1 Inhibitor and Improving the Quality of Life of Hepatocellular Carcinoma-Bearing Mice

Liu

et al. 2023

Iran J Pharm Res

View full text Add to dashboard Cite

show abstract

“…Depression is pervasive and popular in patients with lung cancer (Wang et al, 2022), with an incidence ranging from 19% to 73.9% (Baczewska et al, 2014; Liu et al, 2018; Park et al, 2016). Depression caused by lung cancer is characterised by refractory, high recurrence rate, and multi‐factorial pathogenesis, which has become an essential reason for reducing patients' clinical therapeutic efficacy and quality of life and even leading to adverse health outcomes such as increasing the risk of suicide (Gu et al, 2017; Liu et al, 2022; Santos, 2017). However, most cancer patients with depression are not aware of depressive symptoms early because of a lack of time to rationalise sadness, attribution of somatic symptoms of depression to cancer, avoidance of social stigma, and other reasons (Chochinov, 2001).…”

Section: Introductionmentioning

confidence: 99%

Developing a visual model for predicting depression in patients with lung cancer

Xing

Zhao

Duan

et al. 2022

Journal of Clinical Nursing

View full text Add to dashboard Cite

Aims and objectives: To investigate and analyse the prevalence of depression among patients with lung cancer, identify risk factors of depression, and develop a visual, non-invasive, and straightforward clinical prediction model that can be used to predict the risk probability of depression in patients with lung cancer quantitatively.Background: Depression is one of the common concomitant symptoms of patients with lung cancer, which can increase the risk of suicide. However, the current assessment tools cannot combine multiple risk factors to predict the risk probability of depression in patients. Design:A cross-sectional study. Methods:The clinical data from 297 patients with lung cancer in China were collected and analysed in this cross-sectional study. The clinical prediction model was constructed according to the results of the Chi-square test and the logistic regression analysis, evaluated by discrimination, calibration, and decision curve analysis, and visualised by a nomogram. This study was reported using the TRIPOD checklist.Results: 130 patients with lung cancer had depressive symptoms with a prevalence of 43.77%. A visual prediction model was constructed based on age, disease duration, exercise, stigma, and resilience. This model showed good discrimination at an AUC of 0.842. Calibration curve analysis indicated a good agreement between experimental and predicted values, and the decision curve analysis showed a high clinical utility. Conclusions:The visual prediction model developed in this study has excellent performance, which can accurately predict the occurrence of depression in patients with lung cancer at an early stage and assist the medical staff in taking targeted preventative measures. Relevance to clinical practice:The visual, non-invasive, and simple nomogram can help clinical medical staff to calculate the risk probability of depression among patients with lung cancer, formulate personalised preventive care measures for high-risk groups as soon as possible, and improve the quality of life of patients.

show abstract

Feiyanning downregulating CXCLs/CXCR2 axis to suppress TANs infiltration in the prevention of lung cancer metastasis

Xia

Wang

et al. 2022

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Health-Related Quality of Life and Utility Scores of Lung Cancer Patients Treated with Traditional Chinese Medicine in China

Cited by 3 publications

References 39 publications

Chinese Medicine Enhancing Response Rates to Immunosuppressant PD-L1 Inhibitor and Improving the Quality of Life of Hepatocellular Carcinoma-Bearing Mice

Chinese Medicine Enhancing Response Rates to Immunosuppressant PD-L1 Inhibitor and Improving the Quality of Life of Hepatocellular Carcinoma-Bearing Mice

Developing a visual model for predicting depression in patients with lung cancer

Feiyanning downregulating CXCLs/CXCR2 axis to suppress TANs infiltration in the prevention of lung cancer metastasis

Contact Info

Product

Resources

About